LimmaTech Biologics Acquired by Eli Lilly | Healthcare M&A Deal

Eli Lilly has acquired LimmaTech Biologics, a medical devices business in Massachusetts, for an undisclosed amount. LimmaTech Biologics develops anti-infective vaccine candidates targeting resistant bacterial infections and sexually transmitted diseases, including a Staphylococcus aureus program and preclinical gonorrhea and chlamydia efforts. Lilly acquisitions in healthcare M&A add specialized infectious disease technology and development capabilities to support clinical and preclinical advancement from the Massachusetts base. The deal is an add on acquisition and strategic acquisition by a strategic buyer, with Novo Holdings as a portfolio seller, and it was announced as a definitive agreement with undisclosed terms and timing.